Study Name:
A Study of Pembrolizumab With or Without V940 in Participants With Non-small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Study Dates:
October 21, 2024 - May 16, 2033
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Industry
